Gentherapie gynäkologischer Malignome - ein translationaler Behandlungsansatz

Zusammenfassung

Krebsgentherapie ist vom Grundkonzept her ein vielversprechender neuer Ansatz zur Behandlung von Malignomen, die einer konventionellen Tumortherapie gegenüber resistent sind. Die verschiedenen Ansätze basieren auf den molekularen Unterschieden zwischen normalen Zellen und Tumorzellen, welche für eine gezielte Behandlung genutzt werden. In Bezug auf gynäkologische Malignome wurden in den vergangenen Jahren verschiedene präklinische und klinische Behandlungsansätze entwickelt. Die Daten zeigen eine hohe Therapiesicherheit für die verschiedenen Gentherapieansätze, die klinische Effizienz ist jedoch bis heute unbefriedigend. Eine große Herausforderung liegt somit in der Verbesserung der Effizienz und Spezifität der eingesetzten Gentransfervektoren. Diese Arbeit legt den Schwerpunkt auf aktuelle und zukünftige Gentransferverfahren in der Behandlung gynäkologischer Malignome.

Abstract

Gene therapy is a potentially useful approach for the treatment of malignancies refractory to conventional therapies. Various preclinical and clinical strategies have explored the feasibility of gene therapy for different diseases. Given the urgent need for novel treatment modalities, much of the work to date has focused on gynaecologic malignancies, in particular on ovarian cancer. Although the safety of many approaches has been demonstrated in early phase clinical trials, the efficacy of the different gene therapy approaches has been limited so far. Major challenges include improving gene transfer vectors for enhanced and selective delivery and achieving effective spread of the vector in advanced tumour masses and bulky disease. This review focuses on current and future gene transfer applications for gynaecologic diseases.

Schlüsselwörter

Gentherapie - gynäkologische Tumoren - virale Vektoren

Key words

gene therapy - gynaecologic malignancies - viral vectors

Literatur

• 1 Kanerva A, Hemminki A. Adenoviruses for treatment of cancer.  Ann Med. 2005;  37 33-43
• 2 Kanerva A, Mikheeva G V, Krasnykh V, Coolidge C J, Lam J T, Mahasreshti P J, Barker S D, Straughn M, Barnes M N, Alvarez R D, Hemminki A, Curiel D T. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells.  Clin Cancer Res. 2002;  8 275-280
• 3 Kanerva A, Wang M, Bauerschmitz G J, Lam J T, Desmond R A, Bhoola S M, Barnes M N, Alvarez R D, Siegal G P, Curiel D T, Hemminki A. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses.  Mol Ther. 2002;  5 695-704
• 4 Vanderkwaak T J, Wang M, Gomez-Navarro J, Rancourt C, Dmitriev I, Krasnykh V, Barnes M, Siegal G P, Alvarez R, Curiel D T. An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches.  Gynecol Oncol. 1999;  74 227-234
• 5 Chung I, Schwartz P E, Crystal R G, Pizzorno G, Leavitt J, Deisseroth A B. Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells.  Cancer Gene Therapy. 1999;  6 99-106
• 6 Casado E, Gomez-Navarro J, Yamamoto M, Adachi Y, Coolidge C J, Arafat W O, Barker S D, Wang M H, Mahasreshti P J, Hemminki A, Gonzalez-Baron M, Barnes M N, Pustilnik T B, Siegal G P, Alvarez R D, Curiel D T. Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications.  Clin Cancer Res. 2001;  7 2496-2504
• 7 Breidenbach M, Rein D T, Schondorf T, Khan K N, Herrmann I, Schmidt T, Reynolds P N, Vlodavsky I, Haviv Y S, Curiel D T. A new targeting approach for breast cancer gene therapy using the heparanase promoter.  Cancer Lett. 2006;  240 114-122
• 8 Rein D T, Breidenbach M, Kirby T O, Han T, Siegal G P, Bauerschmitz G J, Wang M, Nettelbeck D M, Tsuruta Y, Yamamoto M, Dall P, Hemminki A, Curiel D T. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.  Clin Cancer Res. 2005;  11 1327-1335
• 9 Breidenbach M, Rein D. Gentherapie - eine neue Therapieoption in der Behandlung gynäkologischer Malignome?.  Geburtsh Frauenheilk. 2005;  65 1127-1129
• 10 Wen W H, Reles A, Runnebaum I B, Sullivan-Halley J, Bernstein L, Jones L A, Felix J C, Kreienberg R, el-Naggar A, Press M F. p 53 mutations and expression in ovarian cancers: correlation with overall survival.  Int J Gynecol Pathol. 1999;  18 29-41
• 11 Shahin M S, Hughes J H, Sood A K, Buller R E. The prognostic significance of p 53 tumor suppressor gene alterations in ovarian carcinoma.  Cancer. 2000;  89 2006-2017
• 12 Kim J, Hwang E S, Kim J S, You E H, Lee S H, Lee J H. Intraperitoneal gene therapy with adenoviral-mediated p 53 tumor suppressor gene for ovarian cancer model in nude mouse.  Cancer Gene Therapy. 1999;  6 172-178
• 13 Kim J, Hwang E S, Kim J S, You E H, Lee S H, Lee J H. Intraperitoneal gene therapy with adenoviral-mediated p 53 tumor suppressor gene for ovarian cancer model in nude mouse.  Cancer Gene Ther. 1999;  6 172-178
• 14 Wolf J K, Mills G B, Bazzet L, Bast Jr. R C, Roth J A, Gershenson D M. Adenovirus-mediated p 53 growth inhibition of ovarian cancer cells is independent of endogenous p 53 status.  Gynecol Oncol. 1999;  75 261-266
• 15 Buller R E, Runnebaum I B, Karlan B Y, Horowitz J A, Shahin M, Buekers T, Petrauskas S, Kreienberg R, Slamon D, Pegram M. A phase I/II trial of rAd/p 53 (SCH 58500) gene replacement in recurrent ovarian cancer.  Cancer Gene Ther. 2002;  9 553-566
• 16 Zeimet A G, Marth C. Why did p 53 gene therapy fail in ovarian cancer?.  Lancet Oncol. 2003;  4 415-422
• 17 Tait D L, Obermiller P S, Hatmaker A R, Redlin-Frazier S, Holt J T. Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability.  Clin Cancer Res. 1999;  5 1708-1714
• 18 Deshane J, Loechel F, Conry R M, Siegal G P, King C R, Curiel D T. Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines.  Gene Therapy. 1994;  1 332-337
• 19 Slamon D J, Godolphin W, Jones L A, Holt J A, Wong S G, Keith D E, Levin W J, Stuart S G, Udove J, Ullrich A. et al . Studies of the HER‐2/neu proto-oncogene in human breast and ovarian cancer.  Science. 1989;  244 707-712
• 20 Deshane J, Cabrera G, Grim J E, Siegal G P, Pike J, Alvarez R D, Curiel D T. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB‐2 single-chain antibody [see comments].  Gynecologic Oncology. 1995;  59 8-14
• 21 Deshane J, Siegal G P, Wang M, Wright M, Bucy R P, Alvarez R D, Curiel D T. Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB‐2 intracellular single-chain antibody for ovarian cancer gene therapy.  Gynecologic Oncology. 1997;  64 378-385
• 22 Alvarez R D, Barnes M N, Gomez-Navarro J, Wang M, Strong T V, Arafat W, Arani R B, Johnson M R, Roberts B L, Siegal G P, Curiel D T. A cancer gene therapy approach utilizing an anti-erbB‐2 single-chain antibody-encoding adenovirus (AD21): a phase I trial.  Clin Cancer Res. 2000;  6 3081-3087
• 23 Rosenfeld M E, Wang M, Siegal G P, Alvarez R D, Mikheeva G, Krasnykh V, Curiel D T. Adenoviral-mediated delivery of herpes simplex virus thymidine kinase results in tumor reduction and prolonged survival in a SCID mouse model of human ovarian carcinoma.  J Mol Med. 1996;  74 455-462
• 24 Tong X W, Block A, Chen S H, Contant C F, Agoulnik I, Blankenburg K, Kaufman R H, Woo S L, Kieback D G. In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration.  Gynecologic Oncology. 1996;  61 175-179
• 25 Alvarez R D, Gomez-Navarro J, Wang M, Barnes M N, Strong T V, Arani R B, Arafat W, Hughes J V, Siegal G P, Curiel D T. Adenoviral-mediated suicide gene therapy for ovarian cancer.  Mol Ther. 2000;  2 524-530
• 26 Hasenburg A, Tong X W, Rojas-Martinez A, Nyberg-Hoffman C, Kieback C C, Kaplan A, Kaufman R H, Ramzy I, Aguilar-Cordova E, Kieback D G. Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer.  Cancer Gene Ther. 2000;  7 839-844
• 27 Hasenburg A, Tong X W, Fischer D C, Rojas-Martinez A, Nyberg-Hoffman C, Kaplan A L, Kaufman R H, Ramzy I, Aguilar-Cordova E, Kieback D G. Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up.  Gynecol Oncol. 2001;  83 549-554
• 28 Boocock C A, Charnock-Jones D S, Sharkey A M, McLaren J, Barker P J, Wright K A, Twentyman P R, Smith S K. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma.  J Natl Cancer Inst. 1995;  87 506-516
• 29 de Vries C, Escobedo J A, Ueno H, Houck K, Ferrara N, Williams L T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor.  Science. 1992;  255 989-991
• 30 Mahasreshti P J, Navarro J G, Kataram M, Wang M H, Carey D, Siegal G P, Barnes M N, Nettelbeck D M, Alvarez R D, Hemminki A, Curiel D T. Adenovirus-mediated soluble FLT‐1 gene therapy for ovarian carcinoma.  Clin Cancer Res. 2001;  7 2057-2066
• 31 Alemany R, Balague C, Curiel D T. Replicative adenoviruses for cancer therapy.  Nat Biotechnol. 2000;  18 723-727
• 32 Vasey P A, Shulman L N, Campos S, Davis J, Gore M, Johnston S, Kirn D H, O'Neill V, Siddiqui N, Seiden M V, Kaye S B. Phase I trial of intraperitoneal injection of the E1B‐55-kd-gene-deleted adenovirus ONYX‐015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer.  J Clin Oncol. 2002;  20 1562-1569
• 33 Bauerschmitz G J, Lam J T, Kanerva A, Suzuki K, Nettelbeck D M, Dmitriev I, Krasnykh V, Mikheeva G V, Barnes M N, Alvarez R D, Dall P, Alemany R, Curiel D T, Hemminki A. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus.  Cancer Res. 2002;  62 1266-1270
• 34 Lam J T, Bauerschmitz G J, Kanerva A, Barker S D, Straughn J M, Wang M, Barnes M N, Blackwell J L, Siegal G P, Alvarez R D, Curiel D T, Hemminki A. Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids.  Cancer Gene Ther. 2003;  10 377-387
• 35 Raki M, Rein D T, Kanerva A, Hemminki A. Gene transfer approaches for gynecological diseases.  Mol Ther. 2006;  14 154-163
• 36 Carson A, Wang Z, Xiao X, Khan S A. A DNA recombination-based approach to eliminate papillomavirus infection.  Gene Ther. 2005;  12 534-540
• 37 Rein D T, Breidenbach M, Nettelbeck D M, Kawakami Y, Siegal G P, Huh W K, Wang M, Hemminki A, Bauerschmitz G J, Yamamoto M, Adachi Y, Takayama K, Dall P, Curiel D T. Evaluation of tissue-specific promoters in carcinomas of the cervix uteri.  J Gene Med. 2004;  6 1281-1289
• 38 Das S, Somasundaram K. Therapeutic potential of an adenovirus expressing p 73 beta, a p 53 homologue, against human papilloma virus positive cervical cancer in vitro and in vivo.  Cancer Biol Ther. 2006;  5 210-217
• 39 Immonen A, Vapalahti M, Tyynela K, Hurskainen H, Sandmair A, Vanninen R, Langford G, Murray N, Yla-Herttuala S. AdvHSV‐tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study.  Mol Ther. 2004;  10 967-972
• 40 Puumalainen A M, Vapalahti M, Agrawal R S, Kossila M, Laukkanen J, Lehtolainen P, Viita H, Paljarvi L, Vanninen R, Yla-Herttuala S. Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses.  Hum Gene Ther. 1998;  9 1769-1774